2. Metabolic Enzyme/Protease Apoptosis
  3. MMP Apoptosis
  4. Edaravone

Edaravone  (Synonyms: 依达拉奉; MCI-186)

目录号: HY-B0099 纯度: 99.89%
COA 产品使用指南

摩尔计算器

Edaravone 是一种新颖的，有效的自由基清除剂，能够抑制大鼠与 MMP-9 有关的脑出血。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Edaravone Chemical Structure

Edaravone Chemical Structure

CAS No. : 89-25-8

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥385
In-stock
5 g ￥350
In-stock
10 g ￥490
In-stock
25 g ￥735
In-stock
50 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Edaravone:

Edaravone 相关抗体

Top Publications Citing Use of Products

    Edaravone purchased from MCE. Usage Cited in: Int Wound J. 2023 Apr 11.  [Abstract]

    Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly reduces the number of apoptotic cells in mice.

    Edaravone purchased from MCE. Usage Cited in: Int Wound J. 2023 Apr 11.  [Abstract]

    Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly increases the protein expression of TGF-β1, VEGF and MMP9 in mice.

    Edaravone purchased from MCE. Usage Cited in: Int Wound J. 2023 Apr 11.  [Abstract]

    Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly promotes VEGF and MMP9 expression in mice.

    Edaravone purchased from MCE. Usage Cited in: Front Physiol. 2020 Jan 15;10:1596.

    TNF-α expression is significantly increased by treating C2C12 cells with 250 µM H2O2. In addition, pretreatment with edaravone at 100 µM, TNF-α expression is significantly suppressed (∗ compared with 0 µM H2O2, p < 0.01; # compared with 250 µM H2O2, p < 0.01).

    Edaravone purchased from MCE. Usage Cited in: Front Physiol. 2020 Jan 15;10:1596.

    After treating C2C12 cells with 250 µM H2O2, viability is significantly decreased, and improvement in survival rate was observed in the group treated with Edaravone at 100 µM (∗compared with 0 µM H2O2, p < 0.01; # compared with 250 µM H2O2, p < 0.01).

    Edaravone purchased from MCE. Usage Cited in: Front Physiol. 2020 Jan 15;10:1596.

    A) HE staining of muscle tissue after artery ligation shows that the cells are round, and reveals infiltration of inflammatory cells in both control (Con) and ob/ob (Ob) mice. (B) MyoD immunostaining is lower in Ob than Con at 7 days after ligation of the femoral artery. However, pretreatment with Edaravone increases the expression of MyoD in obese mice.

    查看 MMP 亚型特异性产品:

    查看所有亚型
    MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    HBMEC-2 EC50
    4.61 μM
    Compound: Edaravone
    Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
    Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
    		[PMID: 31541868]
    PC-12 EC50
    9.2 μM
    Compound: Edaravone
    Neuroprotective activity against 12.5 mM glutamate-induced toxicity in rat PC12 cells assessed as cell viability after 24 hrs by MTT assay
    Neuroprotective activity against 12.5 mM glutamate-induced toxicity in rat PC12 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 28394604]
    Platelet IC50
    0.25 mM
    Compound: Eda
    Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
    Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
    		[PMID: 22827516]
    Platelet IC50
    0.85 mM
    Compound: Eda
    Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
    Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
    		[PMID: 22827516]
    SH-SY5Y EC50
    3.75 μM
    Compound: Edaravone
    Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
    Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
    		[PMID: 31541868]
    体外研究
    (In Vitro)

    Edaravone 对谷氨酸的毒性具有预防和改善作用。Edaravone 的预处理降低了谷氨酸对 SGN 的毒性。Edaravone 减少由谷氨酸引起的细胞凋亡和坏死。Edaravone (500 μM) 的预处理可将这些变化逆转至接近正常水平。Edaravone 对谷氨酸诱导的SGNs细胞凋亡的保护作用与PI3K/Akt通路和Bcl-2蛋白家族有关[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Edaravone 相关抗体:
    体内研究
    (In Vivo)

    Edaravone 通过抑制内皮损伤和改善脑缺血中的神经元损伤来发挥神经保护作用。Edaravone 提供了 NOS 的理想特性：它增加了 eNOS (有益于挽救缺血性中风的 NOS) 并减少了 nNOS 和 iNOS (有害的 NOS)。Edaravone 预处理可减少溶栓处理引起的再灌注后脑水肿和出血事件[1]。Edaravone 显著减少梗死面积，Edaravone 组大鼠的平均梗死面积 (227.6 mm3) 明显低于对照组 (264.0 mm3) . Edaravone 处理还减少了缺血后出血体积 (Edaravone 处理大鼠为 53.4 mm3，对照组为 176.4 mm3)。此外，Edaravone 处理大鼠的出血体积与梗死体积之比 (23.5%) 低于未处理大鼠 (63.2%)[2]。在 Edaravone (20 mg/kg) 处理的大鼠中，胼胝体、生发基质和大脑皮层的星形胶质细胞活性 (胶质原纤维酸性蛋白) 和凋亡细胞 (caspase-3) 减少[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    174.20

    Formula

    C10H10N2O
    CAS 号
    性状

    固体

    颜色

    Off-white to yellow

    中文名称

    依达拉奉
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : 100 mg/mL (574.05 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 5.7405 mL 28.7026 mL 57.4053 mL
    5 mM 1.1481 mL 5.7405 mL 11.4811 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (14.35 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

      生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (14.35 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

      2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    请输入您的动物体内配方组成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
    您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
    连续给药周期超过半月以上，请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.89%

    COA (290 KB) HNMR (230 KB) RP-HPLC (252 KB) MS (68 KB)

    产品使用指南 (1538 KB)
    参考文献
    Cell Assay
    [4]

    Cell viability is quantified by MTT assay and trypan blue staining. MTT (5 mg/mL, 20 μL) is added to each well and incubated for 4 h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570 nm using an ELISA reader.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    Edaravone 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 5.7405 mL 28.7026 mL 57.4053 mL 143.5132 mL
    5 mM 1.1481 mL 5.7405 mL 11.4811 mL 28.7026 mL
    10 mM 0.5741 mL 2.8703 mL 5.7405 mL 14.3513 mL
    15 mM 0.3827 mL 1.9135 mL 3.8270 mL 9.5675 mL
    20 mM 0.2870 mL 1.4351 mL 2.8703 mL 7.1757 mL
    25 mM 0.2296 mL 1.1481 mL 2.2962 mL 5.7405 mL
    30 mM 0.1914 mL 0.9568 mL 1.9135 mL 4.7838 mL
    40 mM 0.1435 mL 0.7176 mL 1.4351 mL 3.5878 mL
    50 mM 0.1148 mL 0.5741 mL 1.1481 mL 2.8703 mL
    60 mM 0.0957 mL 0.4784 mL 0.9568 mL 2.3919 mL
    80 mM 0.0718 mL 0.3588 mL 0.7176 mL 1.7939 mL
    100 mM 0.0574 mL 0.2870 mL 0.5741 mL 1.4351 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Edaravone89-25-8MCI-186依达拉奉MCI186MCI 186MMPApoptosisMatrix metalloproteinasesInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Edaravone
    目录号：
    HY-B0099
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z